Palbociclib for Early Breast Cancer

A phase 2 clinical trial assessing the feasibility of adjuvant palbociclib (IbranceĀ®, Pfizer) and endocrine therapy for patients with early breast cancer reports that it is an effective treatment for these patients. Palbociclib, a targeted therapy drug that inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), causes the cancerous cells to stop dividing and reproducing, ultimately stopping cancer growth. This drug has already been approved for advanced metastatic breast cancer. For the study, publ...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright Ā© 2021 Oncology Data Advisor. All rights reserved.